Cardinal Health, Inc. (CAH)
$
164.93
+2.95 (1.79%)
Key metrics
Financial statements
Free cash flow per share
10.1625
Market cap
39.4 Billion
Price to sales ratio
0.1771
Debt to equity
-2.6048
Current ratio
0.9436
Income quality
1.8879
Average inventory
16.5 Billion
ROE
-0.5014
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Cardinal Health, Inc. operates as an integrated healthcare services and products company providing customized solutions across the United States, Canada, Europe, Asia, and other international markets. The company offers tailored services to hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and home care patients. The company functions in two primary segments: Pharmaceutical and Medical. The Pharmaceutical segment is responsible for distributing both branded and generic pharmaceuticals, specialty pharmaceuticals, and over-the-counter healthcare products. Additionally, it supports pharmaceutical manufacturers and healthcare providers through various services linked to specialty pharmaceuticals; manages nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic and over-the-counter healthcare products; and delivers medication therapy management and patient outcomes services to hospitals, healthcare providers, and payers. The operational income ratio is 0.01 indicating the company's operational profitability margin, while the company recorded an operating income of $1,243,000,000.00 reflecting its earnings from core operations. The income before tax ratio stands at 0.01 which shows the pre-tax margin. On the stock market, the company’s stock is identified with the symbol 'CAH', and the gross profit is $7,414,000,000.00 highlighting the company's profitability from its core operations. Conversely, the Medical segment involves the manufacture, sourcing, and distribution of Cardinal Health branded medical, surgical, and laboratory products, along with a comprehensive range of solutions for healthcare providers. The stock is reasonably priced at $164.40 appealing to a broad array of investors. With a high average trading volume of 2,527,336.00 it demonstrates strong liquidity in the market. The company boasts a mid-range market capitalization of $39,364,997,610.00 positioning it as a steady performer within the industry. As a key player in the Medical - Distribution industry, Cardinal Health significantly contributes to the overall market landscape and embraces its role in driving innovation and growth as part of the Healthcare sector. The combination of a robust product portfolio, strategic market presence, and solid financial metrics underlines the company's commitment to delivering effective healthcare solutions.
Investing in Cardinal Health, Inc. (CAH) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bearish outlook. Always conduct your own research before investing.
Analysts predict Cardinal Health, Inc. stock to fluctuate between $93.17 (low) and $168.44 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-07-03, Cardinal Health, Inc.'s market cap is $39,364,997,610, based on 238,677,000 outstanding shares.
Compared to Eli Lilly & Co., Cardinal Health, Inc. has a Lower Market-Cap, indicating a difference in performance.
Cardinal Health, Inc. pays dividends. The current dividend yield is 1.23%, with a payout of $0.51 per share.
To buy Cardinal Health, Inc. (CAH) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CAH. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Cardinal Health, Inc.'s last stock split was 3:2 on 2001-04-23.
Revenue: $226,827,000,000 | EPS: $3.48 | Growth: 248%.
Visit https://www.cardinalhealth.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $168.44 (2025-07-01) | All-time low: $45.85 (2021-12-01).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
In the closing of the recent trading day, Cardinal Health (CAH) stood at $164.93, denoting a +1.82% move from the preceding trading day.
zacks.com
In the most recent trading session, Cardinal Health (CAH) closed at $161.98, indicating a -1.47% shift from the previous trading day.
247wallst.com
Dividend stocks are a favorite among investors for good reason.
zacks.com
Does Cardinal Health (CAH) have what it takes to be a top stock pick for momentum investors? Let's find out.
zacks.com
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
zacks.com
In the closing of the recent trading day, Cardinal Health (CAH) stood at $165.61, denoting a +1.14% move from the preceding trading day.
zacks.com
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
zacks.com
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
zacks.com
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
youtube.com
Aaron Alt, CFO at Cardinal Health (CAH), joins Diane King Hall at the NYSE set to discuss the company's financial outlook. He describes the drugmaker's share buyback plans and recent FY25 guidance raise.
See all news